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INTRODUCTION
The development of tourist markets and inexpensive
flights, and the stable political situation in the majority of
tourist regions in the world encourage travel. The World Tou-
rism Organisation estimates that the total number of interna-
tional travellers in 2010 will exceed one billion. With increa-
sing international travel, prevention of malaria is an impor-
tant health issue for travellers and seafarers. Approximately
110 countries endemic for malaria are visited by 125 mil-
lion international travellers every year, and more than 30
000 of them contract malaria [1]. Imported malaria has been
a growing health problem in European countries in the last
2 decades [2].
AETIOLOGY
There are five identified species of the parasite caus-
ing human malaria: Plasmodium vivax, Plasmodium ovale,
Plasmodium malariae, Plasmodium falciparum, and Plas-
modium knowlesi. All species are transmitted by the bite of
an infected female Anopheles mosquito [3–5].
EPIDEMIOLOGY
Malaria threatens nearly 40% of the world’s population.
The World Health Organisation (WHO) estimates that each
year 300–500 million cases occur worldwide and more than
two million people die of malaria. Almost 90% of deaths oc-
cur in sub-Saharan Africa where young children are the most
affected. The infection kills one child every 30 seconds; in
absolute numbers, 3000 children under five years of age
die each day. Malaria is particularly dangerous for travellers
from non-endemic areas, and for pregnant women.
More than 15 000 cases of malaria are imported to Eu-
ropean countries every year. Between 1990 and 2003, about
900 people died of malaria in Europe. From the beginning of
1984 to 1st September 2008, there were 22 cases of fatal
malaria registered in Poland. The data do not include the
deaths of Polish citizens in other countries. All these people
were not protected by proper chemoprophylaxis [6–10].
MALARIOUS AREAS
The malarious areas of the world have been divided
into four endemic zones, in each which the resistance of
parasites to drugs is different.
Zone A.  Strains of P. vivax and chloroquine-sensitive
P. falciparum dominate.
Zone B. Ratio P. vivax/P. falciparum approximately
1. Strains of P. vivax and P. falciparum partially or completely
resistant to chloroquine occur.
Zone C. Strains of P. falciparum fully resistant to chlo-
roquine and partially resistant to sulfadoxine-py-
rimethamine and mefloquine dominate.
Zone D. Multidrug resistant strains of P. falciparum
dominate (resistance to chloroquine, sulfadoxine-py-
rimethamine, and mefloquine).
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Zone A comprises Central America and some Caribbean
Islands (Haiti, certain parts of the Dominican Republic).
Zone B covers the Indian subcontinent. Zone C covers South
America (Orinoco delta, the Amazon River basin), sub-Sa-
haran Africa to north-eastern regions of South Africa (includ-
ing Mpumalanga Province with Kruger National Park, other
northern Game Parks, and KwaZulu Natal Province), South
Asia, and Oceania (Papua-New Guinea, Vanuatu, Solomon
Islands). Zone D covers the Indochinese Peninsula (Vietnam,
Lao PDR, Cambodia, Myanmar/Burma, and Thailand).
The big cities and tourist resorts in Southeast Asia are
malaria-free. There is no malaria in Bangkok, Chiang Mai,
Phuket, Pattaya, Hua Hin, Ko Samui, Kuala Lumpur, Pe-
nang, Singapore, Manila, Jakarta, Bali, Hong Kong, or
Rangoon [8, 11–13].
RISK FOR TRAVELLERS/SEAFARERS
The risk of acquiring malaria for travellers depends on
their destination, length of stay, type of accommodation, and
purpose of travel. Other factors determining this risk and
the course of disease include: the intensity and duration of
exposure to mosquito bites; occurrence of drug or multidrug
resistance of the parasite; age, medical history, and health
status of the traveller; pregnancy; use of other medications
that may be incompatible with antimalarials; itinerary and
activities during travel; chances to obtain rapid, qualified
medical care if symptoms occur; and personal knowledge
about malaria. The risk of being infected is highest at the
end of the rainy season. The risk for travellers of symptomat-
ic malaria in non-immune subjects with no chemoprophyla-
xis during a month-long stay in Central America, South Ame-
rica, West Africa, East Africa, the Indian Subcontinent, the
Far East, or the Pacific Islands is 1:10 000; 1:5 000; 1:13;
1:80, 1:250; 1:2 500, and1:16, respectively [6, 8].
PREVENTION OF MOSQUITO BITES
No effective vaccine is currently available. Prevention of
malaria encompasses measures that protect against infes-
tation and against the development of plasmodia in infec-
ted subjects. Measures that protect against infestation are
directed against the mosquito vector. These can be personal
protective measures, e.g. protective clothing, repellents to
the exposed skin, insecticide-impregnated bed nets, or envi-
ronmental protection measures, e.g. use of insecticides.
DEET-based and picaridin-based repellents have been
shown to be most effective. DEET (diethyl-3-methylbenzamide)
remains the gold standard of chemical insect repellents; it is
effective against various species of mosquitoes (Anopheles,
Aedes, Culex), ticks, and other biting insects [6, 8, 11, 14].
CHEMOPROPHYLAXIS
Measures that protect against disease but not against
infection include chemoprophylaxis. Recommendations for
antimalarial prophylaxis in specific geographical locations
are constantly changing. Authoritative up-to-date sources
such as the WHO, CDC, or native guidelines are recommen-
ded [15]. Travellers to malarious areas should seek expert
advice on the prevention of this disease.
Malaria chemoprophylaxis for North Africa
and the Near East
First-line drugs: chloroquine, chloroquine/proguanil
Alternative drugs: atovaquone/proguanil, mefloquine,
doxycycline
Malaria chemoprophylaxis
for sub-Saharan Africa:
First-line drugs: atovaquone/proguanil
Alternative drugs: doxycycline, mefloquine
Malaria chemoprophylaxis for Central Asia and
Indian Subcontinent
First-line drugs: chloroquine/proguanil, atovaquone/
/proguanil
Alternative drugs: mefloquine, doxycycline
Malaria chemoprophylaxis for Indochinese
Peninsula
First-line drugs: atovaquone/proguanil
Alternative drugs: doxycycline
Malaria chemoprophylaxis for Southeast Asia
(Indonesia, Malaysia, Philippines)
First-line drugs: atovaquone/proguanil
Alternative drugs: doxycycline
Malaria chemoprophylaxis for Oceania (Papua
New Guinea, Vanuatu, Solomon Islands)
First-line drugs: atovaquone/proguanil
Alternative drugs: doxycycline, mefloquine
Malaria chemoprophylaxis for Central America,
and Caribbean
First-line drugs: chloroquine, atovaquone/proguanil
Alternative drugs: mefloquine
Malaria chemoprophylaxis for South America
First-line drugs: atovaquone/proguanil, mefloquine
Alternative drugs: doxycycline
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ANTIMALARIALS AND THEIR USE
Chloroquine (common trade names: Aralen,
Arechin, Avloclor, Nivaquine, and Resochin)
The dosage of chloroquine should be calculated in terms
of the base. The normal adult dosage is 300 mg base per
week. Chloroquine should be given 1–2 weeks before en-
tering the malarious area, during the stay, and for 4 weeks
after leaving the risk zone. The drug should be taken week-
ly on the same day of the week. In infants and children, the
weekly dosage is 5 mg base/kg of body weight but regar-
dless of weight should not exceed the adult dose. Chloro-
quine should not be taken by persons with a history of ret-
inopathy, psoriasis, porphyria, epilepsy, or psychosis. Chlo-
roquine prophylaxis may cause pruritus, especially among
people of African descent. Itching of the palms, soles, and
scalp is common in dark-skinned users. Concomitant use
with proguanil can cause mouth ulcers. Chloroquine can
be taken by pregnant women and children, including in-
fants. Due to widespread chloroquine-resistant P. falci-
parum (CRPF), chloroquine alone as malaria prophylaxis is
limited to Central America, Haiti, the Dominican Republic,
and North Africa — including Egypt, Turkey, and the Near
East. Chloroquine in combination with proguanil is recom-
mended for travellers visiting a few countries in Central Asia,
and the Indian Subcontinent [6, 8, 15].
Proguanil (common trade name: Paludrine)
Proguanil is considered a very safe antimalarial drug.
The tablets contain 100 mg of proguanil hydrochloride. Pro-
phylaxis with proguanil (in combination with chloroquine)
should begin 1 day before entering the malarious area and
must be continued during the stay and for 4 weeks after
leaving the risk area. The drug may be taken during preg-
nancy. Use of proguanil alone is not recommended. The
adult dosage is 200 mg daily when combined with chloro-
quine, or 100 mg if in combination with atovaquone. The
side effects such as mouth ulcers and inflammation of the
mouth occur rarely. The recommended prophylactic regi-
men for children is 3 mg/kg daily in combination with chlo-
roquine [6, 8].
Mefloquine (common trade names:
Lariam, Mephaquin)
Mefloquine is a potent, long-acting blood schizonticide
and is effective against all species of Plasmodium. The tab-
lets contain 250 mg of mefloquine base. The standard dose
for adults and children weighing more than 45 kg is one
tablet weekly. Mefloquine prophylaxis should begin 1 week
before entering the malarious area. It should be continued
throughout the later weeks, on the same day of the week,
during the stay in the malarious area, and for 4 weeks af-
ter leaving the area. The prophylactic dose for children must
be based on their weight. The recommended prophylactic
regimen for children weighing more than 5 kg is 5 mg/kg
weekly as a single dose. The main side effects include:
gastrointestinal disturbances, headache, sleep disturban-
ces, strange dreams, depression, and visual disturbances.
Other more severe but rare neuropsychiatric disorders in-
clude: mood changes, confusion, hallucination, agitation,
aggression, paranoia, psychoses, and seizures. Older tra-
vellers and children have fewer adverse reactions than young-
er adults. Women have more adverse reactions than men
[6]. Mefloquine can be started 4 weeks before departure,
so that adverse reactions can be detected before travel
and possible alternatives considered. The drug is cleared
slowly from the body. It has a half-life ranging from 8 to 33
days [12]. This is a disadvantage when side effects occur.
Mefloquine can cause symptoms mimicking decompres-
sion sickness; consequently, it is contraindicated in scuba
divers. Mefloquine should not be taken by people with
a history of epilepsy or psychiatric disorders. This drug is con-
traindicated for use by travellers with a known hypersensi-
tivity to it or to related compounds (e.g. quinine and quini-
dine), and in cardiac conduction disorders. The drug is con-
traindicated during the first trimester of pregnancy due to
the potential risk of embriotoxic or teratogenic effects.
Women of childbearing age should avoid conception du-
ring mefloquine prophylaxis and for 3 months thereafter.
Mefloquine is considered safe for prophylaxis during the
second and third trimester of pregnancy. Inadvertent use
of mefloquine during the first trimester is not an indication
for therapeutic abortion [6, 8, 16].
Doxycycline (common trade names:
Doxycyclinum, Dotur, Supracyclin,
Unidox Solutab, and Vibramycin)
Doxycycline should be taken daily, starting 1 day before
entering the malarious area and continuing until 28 days
after leaving such an area. The normal adult dosage is 100
mg per day. Doxycycline is contraindicated in pregnant or
lactating women and children under 8 years of age. The main
side effects include: esophagitis, gastrointestinal disturban-
ces, oral candidiasis, vulvovaginitis, and pruritus, especially
in the anogenital region. Doxycycline may cause photosensi-
tivity of the skin (an exaggerated sunburn reaction to strong
sunlight). Risk is reduced by avoiding prolonged, direct expo-
sure to the sun, using highly protective and broad-spectrum
sunscreen (these contain both a UVA and UVB blocker), and
taking the drug in the evening [6, 8, 11].
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and physicians of other specialities leads to numerous mis-
takes with prophylaxis. Data concerning drug resistance
are currently being brought up to date. Unfortunately, many
doctors who rarely deal with malaria prophylaxis in every-
day practice often miss information on regions where Plas-
modium falciparum and Plasmodium vivax resistant strains
occur. Hence, constant education and training of physicians
(especially general practitioners) on malaria is necessary.
Unfortunately, there is no antimalarial drug which is per-
fectly effective and perfectly safe. However, adequate
chemoprophylaxis protects against severe, complicated,
and fatal infestation.
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Atovaquone/proguanil (common
trade name: Malarone)
The combination shows synergistic activity. The drug
acts against both the blood and liver phases of the para-
site. Malarone prophylaxis should be started one day be-
fore entering a malaria zone. It should be continued daily
in the malarious area and for 7 days after departure from
it. The standard dose for adults and children weighing more
than 40 kg is one tablet for adults (containing 250 mg of
atovaquone and 100 mg of proguanil) daily. Malarone
should be taken with food or milky drinks at the same time
each day. Paediatric tablets contain 62.5 mg of atovaquone
and 25 mg of proguanil. Dosages for children are as fol-
lows: 5–8 kg — 1/2 paediatric tablet daily; 8–10 kg — 3/4
paediatric tablet daily; 10–20 kg — 1 paediatric tablet dai-
ly; 20–30 kg — 2 paediatric tablets daily; and 30–40 kg
— 3 paediatric tablets daily [14]. Atovaquone/proguanil (Ma-
larone) is recommended by the Centre for Disease Control
(CDC) for the prevention of P. falciparum malaria in chloro-
quine-resistant and multidrug-resistant areas. However, the
drug will not kill the hypnozoites of P.vivax and P.ovale so
travellers at high risk of these infections should receive ter-
minal prophylaxis with primaquine.
In Europe, atovaquone/proguanil (Malarone) is only li-
censed for malaria prophylaxis for 28 days of travel. France
holds a national license that allows prophylaxis to be used
for up to 3 months. In the United Kingdom, atovaquone/
/proguanil can be used for period of up to one year. The
USA, Canada, and Australia allow unrestricted prophylaxis
use [11, 13, 16–18]. Malarone has a low incidence of side
effects, compared to other antimalarials. The most com-
mon adverse reactions are loss of appetite, abdominal pain,
nausea, diarrhoea, dizziness, and headache. Malarone is
not recommended for pregnant women or breast-feeding
women because insufficient data are available for this drug.
Malarone is contraindicated in persons with a known hy-
persensitivity to atovaquone, proguanil, or any component
of the formulation [11, 14–16].
CONCLUSIONS
Antimalarial drugs should be taken with unfailing regu-
larity. Increasing drug resistance of Plasmodium species,
especially P. falciparum and P.vivax to basic antimalarial
remedies gives rise to concern. Drugs which previously
worked well are now becoming ineffective. Numerous
P. falciparum strains have developed resistance to chloro-
quine, sulfadoxine-pyrimethamine, and mefloquine. Resis-
tance to mefloquine is rapidly increasing in the Indochi-
nese Peninsula [11, 14].
The superficial knowledge of malaria (especially on
chemoprophylaxis) of family doctors, general practitioners,
